Verona Pharma plc
VRNA
$63.32
-$2.94-4.44%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 1,127.95% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 1,127.95% | -- | -- |
| Cost of Revenue | -- | -- | 56.94% | -- | -- |
| Gross Profit | -- | -- | 4,436.61% | -- | -- |
| SG&A Expenses | 224.24% | 197.40% | 186.87% | 190.70% | 128.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 246.03% | 190.84% | 156.77% | 124.13% | 20.59% |
| Operating Income | -84.08% | -127.23% | -149.44% | -125.93% | -21.50% |
| Income Before Tax | -147.97% | -202.68% | -202.71% | -142.18% | -3.49% |
| Income Tax Expenses | 781.14% | 2,070.68% | 254.05% | 205.91% | 206.69% |
| Earnings from Continuing Operations | -158.50% | -218.96% | -203.27% | -142.89% | -4.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -158.50% | -218.96% | -203.27% | -142.89% | -4.64% |
| EBIT | -84.08% | -127.23% | -149.44% | -125.93% | -21.50% |
| EBITDA | -84.56% | -127.96% | -150.34% | -126.83% | -21.47% |
| EPS Basic | -153.11% | -210.03% | -192.31% | -123.63% | 9.84% |
| Normalized Basic EPS | -136.49% | -187.80% | -202.22% | -128.66% | 6.86% |
| EPS Diluted | -146.75% | -200.10% | -197.49% | -125.22% | 7.07% |
| Normalized Diluted EPS | -136.49% | -187.80% | -202.22% | -128.66% | 6.86% |
| Average Basic Shares Outstanding | 3.21% | 2.87% | 3.59% | 7.07% | 13.57% |
| Average Diluted Shares Outstanding | 3.21% | 2.87% | 3.59% | 7.07% | 13.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |